Trexquant Investment LP Buys 158,520 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Trexquant Investment LP lifted its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 85.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 343,883 shares of the company’s stock after buying an additional 158,520 shares during the period. Trexquant Investment LP owned about 0.07% of Elanco Animal Health worth $4,164,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ELAN. Wilmington Savings Fund Society FSB bought a new stake in shares of Elanco Animal Health in the 3rd quarter worth approximately $35,000. Jones Financial Companies Lllp raised its stake in shares of Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock valued at $51,000 after purchasing an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. boosted its stake in Elanco Animal Health by 221.2% during the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock worth $60,000 after buying an additional 3,411 shares in the last quarter. MRP Capital Investments LLC bought a new stake in Elanco Animal Health in the 4th quarter valued at $61,000. Finally, Blue Trust Inc. raised its stake in shares of Elanco Animal Health by 47.7% in the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock valued at $71,000 after buying an additional 1,894 shares in the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the transaction, the director now directly owns 111,459 shares in the company, valued at $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.57% of the stock is currently owned by corporate insiders.

Elanco Animal Health Trading Down 5.7 %

Shares of ELAN opened at $9.17 on Friday. The stock has a fifty day moving average price of $11.04 and a two-hundred day moving average price of $12.28. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The company has a market cap of $4.55 billion, a price-to-earnings ratio of 22.91, a PEG ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a 52-week low of $8.80 and a 52-week high of $18.80.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm’s quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter last year, the company earned $0.08 EPS. Analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on ELAN shares. Piper Sandler decreased their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. Barclays decreased their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Morgan Stanley dropped their target price on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus cut their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Finally, UBS Group lowered their price target on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $15.17.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.